Choong Ang Vaccine Laboratory Co. Ltd Asset Resilience Ratio
Choong Ang Vaccine Laboratory Co. Ltd asset resilience ratio. Choong Ang Vaccine Laboratory Co. Ltd (072020) has an Asset Resilience Ratio of 10.35% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 072020 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Choong Ang Vaccine Laboratory Co. Ltd (2014–2025)
Asset resilience ratio of Choong Ang Vaccine Laboratory Co. Ltd from 2014 to 2025. This chart shows how Choong Ang Vaccine Laboratory Co. Ltd's Asset Resilience Ratio has changed over time. Read Choong Ang Vaccine Laboratory Co. Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Choong Ang Vaccine Laboratory Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 072020 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩12.99 Billion | 10.35% |
| Total Liquid Assets | ₩12.99 Billion | 10.35% |
Asset Resilience Insights
- Moderate Liquidity: Choong Ang Vaccine Laboratory Co. Ltd has 10.35% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Choong Ang Vaccine Laboratory Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Choong Ang Vaccine Laboratory Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Choong Ang Vaccine Laboratory Co. Ltd Asset Resilience Ratio by Year (2014–2025)
Choong Ang Vaccine Laboratory Co. Ltd asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Choong Ang Vaccine Laboratory Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.21% | ₩13.77 Billion ≈ $9.33 Million |
₩122.82 Billion ≈ $83.23 Million |
-12.44pp |
| 2024-12-31 | 23.65% | ₩29.15 Billion ≈ $19.76 Million |
₩123.28 Billion ≈ $83.54 Million |
+0.72pp |
| 2023-12-31 | 22.93% | ₩27.42 Billion ≈ $18.58 Million |
₩119.59 Billion ≈ $81.05 Million |
+7.27pp |
| 2022-12-31 | 15.66% | ₩17.98 Billion ≈ $12.19 Million |
₩114.86 Billion ≈ $77.84 Million |
-3.35pp |
| 2021-12-31 | 19.00% | ₩21.47 Billion ≈ $14.55 Million |
₩112.95 Billion ≈ $76.55 Million |
-2.68pp |
| 2020-12-31 | 21.69% | ₩22.77 Billion ≈ $15.43 Million |
₩104.98 Billion ≈ $71.14 Million |
+0.22pp |
| 2019-12-31 | 21.47% | ₩20.73 Billion ≈ $14.05 Million |
₩96.57 Billion ≈ $65.44 Million |
-3.62pp |
| 2018-12-31 | 25.09% | ₩24.27 Billion ≈ $16.45 Million |
₩96.74 Billion ≈ $65.56 Million |
+6.69pp |
| 2017-12-31 | 18.40% | ₩15.02 Billion ≈ $10.18 Million |
₩81.62 Billion ≈ $55.32 Million |
-8.91pp |
| 2016-12-31 | 27.31% | ₩20.09 Billion ≈ $13.61 Million |
₩73.54 Billion ≈ $49.84 Million |
+19.11pp |
| 2015-12-31 | 8.21% | ₩5.10 Billion ≈ $3.45 Million |
₩62.10 Billion ≈ $42.09 Million |
+2.19pp |
| 2014-12-31 | 6.02% | ₩3.65 Billion ≈ $2.47 Million |
₩60.60 Billion ≈ $41.07 Million |
-- |
About Choong Ang Vaccine Laboratory Co. Ltd
Choong Ang Vaccine Laboratory Co., Ltd. engages in the research, development, manufacturing, and sale of animal vaccines in South Korea, Asia, Africa, and the United States. It offers swine, poultry, cattle, canine, feline, wild boar, and raccoon vaccines under the SuiShot, PoulShot, BoviShot, CaniShot, and FeliShot brands. The company was founded in 1968 and is headquartered in Daejeon, South Ko… Read more